Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Share-based Compensation (2018 - 2025)

Bicycle Therapeutics' Share-based Compensation history spans 8 years, with the latest figure at $11.7 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 12.77% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $39.5 million, up 3.63%, while the annual FY2025 figure was $39.5 million, 3.63% up from the prior year.
  • Share-based Compensation reached $11.7 million in Q4 2025 per BCYC's latest filing, up from $8.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $11.7 million in Q4 2025 to a low of $2.6 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $7.4 million, with a median of $8.5 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 166.89% in 2022, then dropped 11.34% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.0 million in 2021, then skyrocketed by 84.73% to $5.5 million in 2022, then soared by 41.01% to $7.8 million in 2023, then soared by 32.27% to $10.3 million in 2024, then increased by 12.77% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Share-based Compensation are $11.7 million (Q4 2025), $8.8 million (Q3 2025), and $9.4 million (Q2 2025).